HIV 感染者在标准治疗失败后，使用锑剂/巴龙霉素治疗后，改用伊曲康唑/米替福新治疗内脏利什曼病。
Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient.
机构信息
Infectious Disease Service, Hospital Universitari de Bellvitge, L'Hospitalet, Barcelona, Spain.
出版信息
Am J Trop Med Hyg. 2010 Jul;83(1):10-2. doi: 10.4269/ajtmh.2010.09-0594.
Abstract
Visceral leishmaniasis is an opportunistic infection that affects human immunodeficiency virus-infected persons in leishmaniasis-endemic areas. The standard treatment may not be effective and relapses are common. We report the case of a human immunodeficiency virus-1-infected patient who had several relapses of visceral leishmaniasis after treatment with standard therapies and responded to a combined therapy.
摘要
内脏利什曼病是一种机会性感染，影响利什曼病流行地区的人类免疫缺陷病毒感染者。标准治疗可能无效，且经常复发。我们报告了 1 例人类免疫缺陷病毒 1 型感染患者，该患者在接受标准治疗后多次复发内脏利什曼病，对联合治疗有反应。
相似文献
1
Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient.
Am J Trop Med Hyg. 2010 Jul;83(1):10-2. doi: 10.4269/ajtmh.2010.09-0594.
2
Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients.
Scand J Infect Dis. 2008;40(1):78-80. doi: 10.1080/00365540701466215. Epub 2007 Jul 6.
3
Post-Kala-Azar dermal leishmaniasis in an HIV-1-infected woman: recovery after amphotericin B following failure of oral miltefosine.
Am J Trop Med Hyg. 2008 Nov;79(5):715-8.
4
Leishmaniasis: an update of current pharmacotherapy.
Expert Opin Pharmacother. 2013 Jan;14(1):53-63. doi: 10.1517/14656566.2013.755515. Epub 2012 Dec 21.
5
Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients.
Scand J Infect Dis. 2008;40(6-7):523-6. doi: 10.1080/00365540701787800.
6
Multiple relapses of visceral leishmaniasis in a patient with HIV in India: a treatment challenge.
Int J Infect Dis. 2014 Aug;25:204-6. doi: 10.1016/j.ijid.2014.02.015. Epub 2014 Jun 10.
7
Successful use of miltefosine and sodium stibogluconate, in combination, for the treatment of an HIV-positive patient with visceral leishmaniasis: a case report and brief review of the literature.
Ann Trop Med Parasitol. 2009 Jul;103(5):455-9. doi: 10.1179/136485909X451753.
8
Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
Lancet. 2011 Feb 5;377(9764):477-86. doi: 10.1016/S0140-6736(10)62050-8. Epub 2011 Jan 20.
9
Combination Treatment for Visceral Leishmaniasis Patients Coinfected with Human Immunodeficiency Virus in India.
Clin Infect Dis. 2015 Oct 15;61(8):1255-62. doi: 10.1093/cid/civ530. Epub 2015 Jun 30.
10
A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
Clin Infect Dis. 2006 Aug 1;43(3):357-64. doi: 10.1086/505217. Epub 2006 Jun 20.
引用本文的文献
1
Immucillins ImmA and ImmH Are Effective and Non-toxic in the Treatment of Experimental Visceral Leishmaniasis.
PLoS Negl Trop Dis. 2015 Dec 23;9(12):e0004297. doi: 10.1371/journal.pntd.0004297. eCollection 2015 Dec.
2
Visceral leishmaniasis and HIV coinfection in the Mediterranean region.
PLoS Negl Trop Dis. 2014 Aug 21;8(8):e3021. doi: 10.1371/journal.pntd.0003021. eCollection 2014 Aug.
3
A screen-and-treat strategy targeting visceral leishmaniasis in HIV-infected individuals in endemic East African countries: the way forward?
PLoS Negl Trop Dis. 2014 Aug 7;8(8):e3011. doi: 10.1371/journal.pntd.0003011. eCollection 2014 Aug.
本文引用的文献
1
Paromomycin.
Trans R Soc Trop Med Hyg. 2009 Jul;103(7):653-60. doi: 10.1016/j.trstmh.2008.09.008. Epub 2008 Oct 23.
2
Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus (HIV) infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine and paromomycin administration.
Int J Antimicrob Agents. 2008 Jun;31(6):590-2. doi: 10.1016/j.ijantimicag.2008.02.007. Epub 2008 May 5.
3
The relationship between leishmaniasis and AIDS: the second 10 years.
Clin Microbiol Rev. 2008 Apr;21(2):334-59, table of contents. doi: 10.1128/CMR.00061-07.
4
Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients.
Scand J Infect Dis. 2008;40(1):78-80. doi: 10.1080/00365540701466215. Epub 2007 Jul 6.
5
Injectable paromomycin for Visceral leishmaniasis in India.
N Engl J Med. 2007 Jun 21;356(25):2571-81. doi: 10.1056/NEJMoa066536.
6
[Oral miltefosine to treat leishmaniasis].
Biomedica. 2006 Oct;26 Suppl 1:207-17.
7
Treatment of visceral leishmaniasis.
Expert Opin Pharmacother. 2005 Dec;6(16):2821-9. doi: 10.1517/14656566.6.16.2821.
8
Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy.
J Clin Microbiol. 2002 Mar;40(3):762-7. doi: 10.1128/JCM.40.3.762-767.2002.
9
Drug resistance in Indian visceral leishmaniasis.
Trop Med Int Health. 2001 Nov;6(11):849-54. doi: 10.1046/j.1365-3156.2001.00778.x.
10
Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study.
Medicine (Baltimore). 2001 Jan;80(1):54-73. doi: 10.1097/00005792-200101000-00006.
Zotero 插件